Education
About Us
Working with TipRanks
Follow Us
Verrica Pharmaceuticals (VRCA)
NASDAQ:VRCA
Part 1: Vp-315 3 Day Dosing/Week, Part 2: Vp-315 3 Day Dosing/Week - Loading Dose, Part 2: Vp-315 2 Day Dosing/Week - Split Dose, Part 2: Vp-315 3 Day Dosing/Week - Split Dose
Basal Cell Carcinoma, Skin Cancer, Carcinoma, Cancer Of The Skin, Basal Cell, Cancer Of The Skin
Phase II
Completed
Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma
Dec 13, 2021
―
Vp-102 And Applicator
Skin Diseases, Papillomavirus Infections, Warts, Sexually Transmitted Diseases, Skin Diseases, Viral, Skin Diseases, Infectious, Condylomata Acuminata, Sexually Transmitted Diseases, Viral
Phase II
Completed
A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts
Jun 06, 2019
―
Vp-102 Cantharidin Topical Film Forming Solution, Vp-102 Cantharidin, Topical Film Forming Solution
Skin Diseases, Virus Diseases, Papillomavirus Infections, Warts, Warts Hand, Verruca, Common Wart, Dna Virus Infections, Skin Diseases, Viral, Skin Diseases, Infectious, Tumor Virus Infections, Verruca Vulgaris
Phase II
Completed
Cantharidin and Occlusion in Verruca Epithelium
Mar 21, 2018
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Verrica Pharmaceuticals (VRCA) have in its pipeline
VRCA is currently developing the following drugs: Part 1: Vp-315 3 Day Dosing/Week, Part 2: Vp-315 3 Day Dosing/Week - Loading Dose, Part 2: Vp-315 2 Day Dosing/Week - Split Dose, Part 2: Vp-315 3 Day Dosing/Week - Split Dose, Vp-102 And Applicator, Vp-102 Cantharidin Topical Film Forming Solution, Vp-102 Cantharidin, Topical Film Forming Solution. These drug candidates are in various stages of clinical development as the company works toward FDA approval.